CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma-Reference-Cited by-同舟云学术

CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma

Published:2021-01-01 Issue:1 Volume:10 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

De Veirman Kim¹,Puttemans Janik²,Krasniqi Ahmet²,Ertveldt Thomas³,Hanssens Heleen²,Romao Ema⁴,Hose Dirk¹,Goyvaert Cleo³,Vlummens Philip¹⁵^ORCID,Muyldermans Serge⁴,Breckpot Karine³,Bruchertseifer Frank⁶,Morgenstern Alfred⁶,D’Huyvetter Matthias²,Devoogdt Nick²

Affiliation:

1. Department of Hematology and Immunology, Vrije Universiteit Brussel, Brussels, Belgium

2. Department of Medical Imaging, Laboratory for in Vivo Cellular and Molecular Imaging, Vrije Universiteit Brussel, Brussels, Belgium

3. Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium

4. Department of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium

5. Department of Clinical Hematology, Ghent University Hospital, Ghent, Belgium

6. European Commission, Joint Research Centre (JRC), Karlsruhe, Germany

Funder

Stimulans, International Myeloma Foundation

Fonds Wetenschappelijk Onderzoek

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2021.2000699

Reference43 articles.

1. How I treat the young patient with multiple myeloma

2. Multiple myeloma: the (r)evolution of current therapy and a glance into future

3. Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficient α and β− radionuclide therapy targeting fibroblast activation protein-α in an aggressive preclinical mouse tumour model;European Journal of Nuclear Medicine and Molecular Imaging;2024-09-06

2. Case report: Dual-targeted BCMA and CS1 CAR-T-cell immunotherapy in recurrent and refractory extramedullary multiple myeloma;Frontiers in Immunology;2024-07-30

3. Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?;European Journal of Nuclear Medicine and Molecular Imaging;2024-04-27

4. CD274 (PD-L1) negatively regulates M1 macrophage polarization in ALI/ARDS;Frontiers in Immunology;2024-02-19

5. Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors;Trends in Cancer;2023-11